Dr. Van den Abbeele is Chair, Department of Imaging and Founding Director of the Center for Biomedical Imaging in Oncology at the Dana-Farber Cancer Institute, Co-Director of the Tumor Imaging Metrics Core at the Dana-Farber/Harvard Cancer Center, and an Associate Professor of Radiology at Harvard Medical School. She holds a BA and MD from the University of Louvain in Belgium. Following a residency in Pediatrics at the University of Louvain and a Neonatology fellowship at Vanderbilt University Medical Center in Nashville, TN, she completed a residency in Nuclear Medicine, a fellowship in Radiology at the Brigham and Women’s Hospital (BWH) in Boston, MA and 7 years of basic science research in the Radiation Biology lab led by Drs. Adelstein and Kassis at Harvard Medical School. She then joined the Dana-Farber Cancer Institute as the Chief of Nuclear Medicine in 1994 and the Chair of the Department of Imaging in 2007. Dr. Van den Abbeele is a Fellow of the American College of Radiology (FACR) and a Fellow of the International Cancer Imaging Society (FICIS). Dr. Van den Abbeele has received several awards and serves on national and international scientific advisory boards and review panels, NCI program progress review groups, and several local, national and international committees.
Research and Expertise: Dr. Van den Abbeele is nationally and internationally known for her translational research in molecular imaging building upon her pioneering work in monitoring response to molecularly-targeted therapy and immunotherapy in several cancers, for developing an integrated clinical and research cancer imaging department and for leading the implementation and development of quantitative metrics in cancer imaging. Dr. Van den Abbeele has mentored more than 100 trainees, served as a PhD thesis advisor and reviewer, authored more than 200 scientific articles and abstracts, co-edited 2 textbooks, authored and co-authored 25 book chapters, and presented numerous lectures and workshops nationally and internationally.
Major areas of research: Enabling translational cancer research, probe and drug development, increasing the understanding of biologic processes and facilitating the design, size, duration and execution of pre-clinical and clinical trials including co-clinical trials through the use of imaging including molecular imaging, quantitative imaging metrics and a multidisciplinary approach.